IMI Antimicrobial resistance accelerator programme

IMI (Innovative Medicines Initiative) recently published topics under consideration for  inclusion in future IMI Calls for proposals.

One of the programme focus and Antimicrobial resistance with 3 pillars:

Pillar A: Capability building network (CBN)
Pillar B: Tuberculosis drug development network (TBDDN)
Pillar C: Company-specific portfolio building networks (PBNs)


More informations and drafts topic texts are available on IMI Future Topics page.

EC vaccination consultation

The European Commission launch a public consultation in preparation of a proposal for a Council Recommendation on Strengthened Cooperation against Vaccine Preventable Diseases to be adopted in 2018.

The purpose of the public consultation is to is to collect the views and input of citizens, administrations, associations and other relevant organisations to feed into the process of drafting the proposal. 

The 3 issues of the consultation are:

  1. Tackling vaccine heistancy
  2. Sutainable vaccine policies in EU
  3. EU action

Questionnaire to be filled online is available in all EU languague here

Deadline: 15 March 2018

Malacidins: a new antibiotic against MRSA

Researchers from the Rockefeller University in New York city (USA) discovered a new family of antibiotic that the team called 'malacidins' when analysis bacteria from the soil to discover new natural products (made by cultured bacteria).

This family of compounds kills many pathogen, including MRSA (Methicillin-resistance Staphyllococus Aureus), which is very difficult to treat nowadays, as show in a rat model of wound for MRSA. A new hope for patients? 

For a short version of the story, click here

The full article is available here

MOOC on Tuberculosis

If you are curious about tuberculosis, a new online course on the topic will start on 29 January 2018, in English with French subtitles.

This course, launched by Institut Pasteur in collaboration with Shenzhen Nanshan Center for Chronic Disease Control will cover a wide range of aspects, from basic knowledge to the latest findings, clinical aspects, epidemiology, TB in children, risk factors (especially genetic factors), the immune response, vaccines, and methods for detecting and treating drug-resistant TB, etc.

The MOOC is designed to offer a broad overview of TB. It is particularly aimed at healthcare professionals and public health workers, microbiologists, pharmacists, scientists and students in life sciences.

For more information, click here

The flyer

Broadcast of EMA-ECDC joint meeting on antimicrobial resistance

The European Medicines Agency (EMA) is organising a joint meeting with the European Centre for Disease Prevention and Control (ECDC) to discuss antimicrobial resistance.The event will take place at EMA’s premises in London on 19 September 2017 and will be broadcast live on the EMA website.

You can access the notice announcing the event here.

You can access the broadcast here.

This meeting will bring together representatives of the World Health Organization (WHO), the European Commission, the European Union (EU) Member States, patients’ and consumers’ organisations, healthcare professionals’ organisations and academia. 

A report on the meeting will be published on the EMA website in due course.


The NAREB project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 604237.